$NTLA
Intellia Therapeutics, Inc
XNAS•Health Care•In Vitro & in Vivo Diagnostic Substances
Why is NTLA down today? It is at $10.95 (-0.18%), and our scanner flagged it 125 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment NTLA spikes, and full due diligence on NTLA — key stats, earnings, dilution and insider activity. Free.
Get free $NTLA alerts the moment volume spikes
Our scanner flagged $NTLA 125 times in the last 30 days. Create a free account to track $NTLA, build a watchlist, and get instant unusual-volume alerts — plus 5 free premium days, no card needed.
No card · 5 premium days · join 800+ traders
Key Stats
- Price
- $10.95
- Change today
- -0.18%
- Previous close
- $10.97
- 52-week range
- $7.95 – $28.25
- Market cap
- $1.53B
- Institutional own.
- 91.18%
- Total held
- 94.2%
- Tradeable float
- 8.1M 6% of shares · after 3% insiders + 91% institutions
- Short interest
- 45.8M ▼ -7% vs prior · as of 2026-07-15
- Days to cover
- 9.8d
- Avg daily volume
- 5.9M
- Sector
- Health Care
- Industry
- In Vitro & in Vivo Diagnostic Substances
- Exchange
- XNAS
- 5m
- 2.8x
- 15m
- 0.7x
- 1hthin
- 1.3x
- 1D
- 0.0x
Get free NTLA + market alerts in your inbox
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Why is $NTLA moving today?
NTLA is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 4 unusual-volume and momentum alerts on NTLA today, peaking at 10.5x its normal volume. Fresh from the SEC: Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates. A material company disclosure like this is often the real catalyst behind a move of this size.
Likely catalystIntellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates, from the latest SEC filing. Read it →Analyst data via Nasdaq. Not investment advice.
Insiders
Insiders buying7 buys, 3 sells last 3 months (16/15 over 12 months)Show 12 recent transactionsMinimize 12 recent transactions
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Dulac Edward J Iii Officer | Sold (automatic/other) | -8K | sold 5.2% | 148K | $91K at $11.25 | Jul 22, 26 |
Dulac Edward J Iii Officer | Sold (automatic/other) | -5K | sold 2.9% | 156K | $84K at $18.00 | Jul 2, 26 |
Dube Michael P Officer | Sold (automatic/other) | -3K | sold 3.8% | 67K | $44K at $16.78 | Jul 1, 26 |
Bhanji Muna Director | Acquired (grant/award) | +9K | added 34% | 36K | n/a | Jun 9, 26 |
Chase William J Director | Acquired (grant/award) | +9K | added 6.8% | 144K | n/a | Jun 9, 26 |
Cohen Fred E Director | Acquired (grant/award) | +9K | added 4.4% | 217K | n/a | Jun 9, 26 |
Goff Brian Director | Acquired (grant/award) | +9K | added 39% | 33K | n/a | Jun 9, 26 |
Goodman Jesse Director | Acquired (grant/award) | +9K | added 38% | 34K | n/a | Jun 9, 26 |
Keresty Georgia Director | Acquired (grant/award) | +9K | added 29% | 41K | n/a | Jun 9, 26 |
Verwiel Frank Director | Acquired (grant/award) | +9K | added 35% | 35K | n/a | Jun 9, 26 |
Clark Eliana Officer | Sold (automatic/other) | -607 | sold 0.6% | 94K | $8K at $13.78 | Mar 2, 26 |
Basta James Officer | Sold (automatic/other) | -1K | sold 0.8% | 157K | $17K at $13.78 | Mar 2, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Dilution watch
Recent offeringAt-the-market (ATM) offering active — the company can keep selling new shares into the market over time (ongoing). If $NTLA runs, these filings show who may be positioned to sell new or newly-registered shares into the move.
- At-the-market (ATM) program — sells new shares into the market gradually over time · Priced at $10.75/share
Sourced from SEC EDGAR filings (last 9 months); terms read straight from the filing text where available. Ongoing = an at-the-market (ATM) program still selling over time or a live shelf, so it can keep diluting; Completed = a one-time priced sale that already finished. A shelf (S-3) stays effective ~3 years. Form type signals dilution capacity, not an exact share count, and we can't confirm how much of a shelf or ATM remains unused. Not investment advice.
$NTLA Sentiment
BullishBlend of news sentiment, today’s move, and community votes. Not investment advice.
$NTLA Activity
News, unusual-volume alerts, AI-trader trades and community chatter — the whole story, newest first.
Stocks similar to NTLA
Comparable names in in vitro & in vivo diagnostic substances, closest in size first.
NTLA stock FAQ
Why is $NTLA moving today?
NTLA is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 4 unusual-volume and momentum alerts on NTLA today, peaking at 10.5x its normal volume. Fresh from the SEC: Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates. A material company disclosure like this is often the real catalyst behind a move of this size.
What is the NTLA stock price today?
NTLA last traded at $10.95, down 0.18% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Where can I see live NTLA alerts?
The NTLA Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged NTLA 125 times in the last 30 days.
What exchange is NTLA on?
NTLA (Intellia Therapeutics, Inc) trades on XNAS, with a market cap of about $1.53B in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector.
Is NTLA good for day trading?
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge NTLA for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.